Literature DB >> 28742400

Role of Different CD40 Polymorphisms in Graves' Disease and Hashimoto's Thyroiditis.

Dongguo Wang1, Jiayu Chen2, Huanyuan Zhang3, Fangfang Zhang3, Linjun Yang4, Yonghua Mou5.   

Abstract

Genome-wide association studies have led to the discovery of several susceptibility genes related to autoimmune thyroid diseases (AITDs). However, controversial results have been reported regarding the role of single-nucleotide polymorphism (SNP) of CD40 in the disease susceptibility. The objective of this study was to identify the relationship of the polymorphisms of three sites of CD40 with the susceptibility to AITD in the Chinese population. We genotyped three polymorphisms of CD40: C/T -1 SNP, 58038T site of the third exon and C64610G site of the ninth exon in 196 GD cases, 121 HT cases and 122 control subjects. The three putative polymorphism sites were amplified by PCR for sequencing and analysis. The genotype frequencies of CD40 -1 C/C genotype and C allele were significantly higher in the GD group than those in normal control. For the C64610G polymorphism, the C/G genotype was significantly more frequent in HT group than in control group, and the G allele frequencies in the GD and HT group were both higher than those in control group. These results indicated that there exist different susceptibility loci for AITD within CD40, each contributing a different effect in the onset and development of AITDs.

Entities:  

Keywords:  Autoimmune thyroid diseases; CD40; single nucleotide polymorphism

Mesh:

Substances:

Year:  2017        PMID: 28742400     DOI: 10.1080/08820139.2017.1319382

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  8 in total

Review 1.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

2.  Association of soluble CD40 levels with -1 C > T CD40 polymorphism and chronic kidney disease in systemic lupus erythematosus.

Authors:  Raziel Tapia-Llanos; José F Muñoz-Valle; Ilce V Román-Fernández; Miguel Marín-Rosales; Diana C Salazar-Camarena; Alvaro Cruz; Gerardo Orozco-Barocio; Jorge A Guareña-Casillas; Edith Oregon-Romero; Claudia A Palafox-Sánchez
Journal:  Mol Genet Genomic Med       Date:  2019-10-23       Impact factor: 2.183

Review 3.  Genetic Susceptibility to Joint Occurrence of Polycystic Ovary Syndrome and Hashimoto's Thyroiditis: How Far Is Our Understanding?

Authors:  Natalia Zeber-Lubecka; Ewa E Hennig
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

4.  Compelling Evidence Linking CD40 Gene With Graves' Disease in the Chinese Han Population.

Authors:  He Jiang; Fei-Fei Yuan; Hai-Ning Wang; Wei Liu; Xiao-Ping Ye; Shao-Ying Yang; Hui-Jun Xie; Sha-Sha Yu; Yu-Ru Ma; Le-Le Zhang; Shuang-Xia Zhao; Huai-Dong Song
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-18       Impact factor: 5.555

5.  Clinical effect of methimazole combined with selenium in the treatment of toxic diffuse goiter in children.

Authors:  Xiao-Hong Zhang; Gao-Pin Yuan; Ting-Li Chen
Journal:  World J Clin Cases       Date:  2022-02-06       Impact factor: 1.337

6.  Variations in CD14 Gene Are Associated With Autoimmune Thyroid Diseases in the Chinese Population.

Authors:  Xi Jia; Bing Wang; Qiuming Yao; Qian Li; Jinan Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2019-01-16       Impact factor: 5.555

7.  Correlation of TSHR and CTLA-4 Single Nucleotide Polymorphisms with Graves Disease.

Authors:  Weihua Sun; Xiaomei Zhang; Jing Wu; Wendi Zhao; Shuangxia Zhao; Minglong Li
Journal:  Int J Genomics       Date:  2019-09-03       Impact factor: 2.326

Review 8.  Genetics, Epigenetics, Cellular Immunology, and Gut Microbiota: Emerging Links With Graves' Disease.

Authors:  Fangyu Zhou; Xin Wang; Lingjun Wang; Xin Sun; Guiqin Tan; Wenwen Wei; Guangbing Zheng; Xiaomin Ma; Dan Tian; Hongsong Yu
Journal:  Front Cell Dev Biol       Date:  2022-01-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.